🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Evaluate the Safety and Feasibility of Same-Day Bilateral Epithelium-On Corneal Cross-Linking for Keratoconus

RecruitingPhase 4Ages 13 Years - anyAllGlaukos Corporation
NCT07629557 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Clinical trial to evaluate the safety and feasibility of corneal cross-linking in both eyes on the same day in subjects with keratoconus.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Provide written informed consent * Willing and able to comply with study instructions and follow-up visits * Diagnosis of keratoconus in each eye Exclusion Criteria: * Known allergy or sensitivity to study medications * History of corneal disease * Prior corneal cross-linking in either eye * Pregnant, nursing, or planning pregnancy during the study period * Participated in other investigational drug or device trial within 30 days of the study
💊

What it tests

  • Riboflavin Ophthalmic Solutions
  • UV-A Irradiation System
📍

Where

1 site
Glaukos Investigative Site
Westerville, United States
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy